Acquisition strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough.
AMT-061 program, currently in Phase III trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with hemophilia B
As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challenge
Ryan Carpentier, Executive Director of Business Development, Cryoport09.23.19
Facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell & gene therapy products by 2021